07th week of 2014 patent applcation highlights part 37 |
Patent application number | Title | Published |
20140044696 | METHODS FOR CULTURING STEM AND PROGENITOR CELLS - The present application describes a method of culturing, expanding or growing stem or stem-like cells or induced pluripotent stem cells on a surface, including attaching the cells to the surface through a ligand that binds to the surface and the cells. | 2014-02-13 |
20140044697 | METHODS FOR TREATING LYSOSOMAL ACID LIPASE DEFICIENCY - The present invention provides compositions and methods for effective treatment of a lysosomal acid lipase deficiency (LALD) disease, in particular, Wolman's disease and Cholesteryl Ester Storage Disease (CESD). Among other things, the present invention provides a method of treating developmental impairment or malnutrition in an individual suffering from a lysosomal acid lipase deficiency (LALD) disease, comprising administering to the individual a therapeutic effective amount of a lysosomal acid lipase. | 2014-02-13 |
20140044698 | METHOD OF PEPTIDE HYDROLYSIS, PEPTIDASE, THE COMPOSITION FOR USE AS A BACTERIOSTATIC AND BACTERICIDAL AGENT, A KIT AND THE USES OF THE ACTIVE FORM OF LYTM FROM S. AUREUS OR DERIVATIVES THEREOF - The invention relates to new method of peptide hydrolysis, in particular of the cell walls of Gram-positive bacteria, wherein the active form of LytM or derivative thereof is contacted with a peptide substrate, preferably with the cell walls of Gram-positive bacteria, in an aqueous environment of conductivity lower than 10 mS/cm. The invention also relates to composition comprising active form of LytM or derivative thereof and new uses of active form of LytM or derivative thereof. | 2014-02-13 |
20140044699 | PROTEINS HAVING ACQUIRED A-GALACTOSIDASE ACTIVITY - The present invention provides a pharmaceutical composition comprising a protein having α-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an α-galactosidase activity through alteration of the structure of the active site of wild-type human α-N-acetylgalactosaminidase. | 2014-02-13 |
20140044700 | METHODS AND COMPOSITIONS FOR IMPROVING GROWTH OF MEAT-TYPE POULTRY - The present invention provides methods of improving growth performance, improving the efficiency of feed utilization, increasing feed digestibility, and decreasing mortality of immature and developing animals receiving animal feed. Methods of producing a crude keratinise enzyme extract and animal feed supplements for achieving the same are also provided. | 2014-02-13 |
20140044701 | Factor VII polypeptides that are modified and uses thereof - Modified factor VII polypeptides and uses thereof are provided. Such modified FVII polypeptides include Factor VIIa and other forms of Factor VII. Among modified FVII polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 2014-02-13 |
20140044702 | DIAGNOSIS AND TREATMENTS RELATING TO TH2 INHIBITION - Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors. | 2014-02-13 |
20140044703 | HUMAN MONOCLONAL ANTIBODY HUMAN CD134 (OX40) AND METHODS OF MAKING AND USING SAME - The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods. | 2014-02-13 |
20140044704 | TREATMENT OF METASTATIC BREAST CANCER - The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positive metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel. | 2014-02-13 |
20140044705 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH BENDAMUSTINE - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with bendamustine for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and bendamustine. | 2014-02-13 |
20140044706 | MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER - Methods and compositions are provided for treating hyperproliferative disorders in patients with a PI3K inhibitor, GDC-0032 as a single agent or in combination with chemotherapeutic agents. | 2014-02-13 |
20140044707 | ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES TEHREOF - Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTPβ), and uses thereof. | 2014-02-13 |
20140044708 | Process for lowering the viscosity of highly concentrated protein solutions - A process of lowering the viscosity of a solution includes preparing a solution comprising a compound of formula I, at a concentration in the final formulation of between 10 and 250 mM, and a protein having at least one antibody fragment whose concentration is between 50 and 350 mg/mL and whose pH is between 5 and 8. | 2014-02-13 |
20140044709 | TREATMENT OF HER2-POSITIVE CANCER WITH PACLITAXEL AND TRASTUZUMAB-MCC-DM1 - The present invention relates to combination therapy with paclitaxel, trastuzumab-MCC-DM1 and optionally, pertuzumab. | 2014-02-13 |
20140044710 | VON WILLEBRAND FACTOR SPECIFIC BINDERS AND METHODS OF USE THEREFOR - The invention provides new uses for specific binders to the A1 domain of the von Willebrand Factor (vWF), in particular the use in patients with stable angina undergoing elective percutaneous coronary intervention. Furthermore, dosing schedules and use of suitable assays such as RIPA and RICO in the particular disease settings are provided. | 2014-02-13 |
20140044711 | Therapeutic Nuclease Compositions and Methods - Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal. | 2014-02-13 |
20140044712 | Methods of Improving the Therapeutic Efficacy and Utility of Antibody Fragments - The present disclosure relates to methods and uses of improving the therapeutic efficacy and utility of antibody fragments by employing anti-epitope-tagging technologies. | 2014-02-13 |
20140044713 | Compounds - The present invention relates to compounds that act as agonists of the Wnt signalling pathway, compositions comprising these compounds and the uses of these compounds, both therapeutic and in research. The invention also provides methods of identifying compounds that act as agonists of the Wnt signalling pathway. | 2014-02-13 |
20140044714 | HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR GLYPICAN-3 AND USE THEREOF - Described herein is the identification of human monoclonal antibodies that bind GPC3 or heparan sulfate (HS) chains on GPC3 with high affinity. The antibodies described herein are capable of inhibiting HCC cell growth and migration. Provided are human monoclonal antibodies specific for GPC3 or HS chains on GPC3, including immunoglobulin molecules, such as IgG antibodies, as well as antibody fragments, such as single-domain VH antibodies or single chain variable fragments (scFv). Further provided are compositions including the antibodies that bind GPC3 or HS chains on GPC3, nucleic acid molecules encoding these antibodies, expression vectors comprising the nucleic acids, and isolated host cells that express the nucleic acids. Methods of treating cancer and/or inhibiting tumor growth or metastasis are also provided. Further provided are methods of detecting cancer in a subject and confirming a diagnosis of cancer in a subject. | 2014-02-13 |
20140044715 | TREATING ALLERGIC AIRWAY DISORDERS USING ANTI-IL-20 RECEPTOR ANTIBODIES - Treatment of an allergic airway disorder (e.g., asthma or bronchial airway obstruction) using anti-IL-20R1 antibodies such as mAb51D, mAb7GW, or functional variants thereof. | 2014-02-13 |
20140044716 | VHNAR ANTI-CYTOKINE DOMAINS - The present invention concerns therapeutic compositions containing proteins that are the variable regions of IgNAR immunoglobulins, denominated vNAR, that specifically bind and neutralizes cytokines involved in a diversity of process such as inflammation and neovascularization, its ability to reach, bind, and neutralize the activity of one antigenic molecule localized in an immunoprivileged organs, are also described. | 2014-02-13 |
20140044717 | LYOPHILIZED FORMULATIONS - The invention is directed to a method for producing a polypeptide composition comprising: combining a polypeptide with a volatile additive to form a liquid mixture and lyophilizing the liquid mixture to obtain a lyophilized polypeptide composition. | 2014-02-13 |
20140044718 | ANTIBODIES AGAINST IL-17BR - The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease. | 2014-02-13 |
20140044719 | ANTIBODIES AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) AND METHODS OF USE - Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided. | 2014-02-13 |
20140044720 | HUMAN MONOCLONAL ANTIBODIES THAT BIND INSULIN-LIKE GROWTH FACTOR (IGF) I AND II - Disclosed herein are human monoclonal antibodies that specifically bind both IGF-I and IGF-II with picomolar affinity and potently inhibit the IGF-IR signal transduction function. These antibodies are active in both an IgG and a scFv format. Bispecific forms of these antibodies are also disclosed. Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors are also disclosed herein. Also disclosed are pharmaceutical compositions including these antibodies. Methods are provided for treating a subject with cancer and for inhibiting phosphorylation of the insulin-like growth factor-I receptor. Methods are also provided for diagnosing cancer. | 2014-02-13 |
20140044721 | ANTI-GB3 ANTIBODIES USEFUL IN TREATING DISORDERS ASSOCIATED WITH ANGIOGENESIS - The present invention lies in the field of new cancer therapies, more precisely in the field of antiangiogenic compounds. It notably concerns anti-Gb3 antibodies having specific CDR sequences, as well as the use of anti-Gb3 antibodies not coupled to a therapeutic molecule in the treatment of diseases associated with angiogenesis, such as solid tumors. | 2014-02-13 |
20140044722 | ANTI-SOD1 ANTIBODIES AND USES THEREOF - The present invention features anti-SOD1 antibodies and methods of using the antibodies for the treatment of amyotrophic lateral sclerosis (ALS) or the amelioration of symptoms associated with ALS. | 2014-02-13 |
20140044723 | ANTI-PLATELET MEMBRANE GLYCOPROTEIN VI MONOCLONAL ANTIBODY - The present invention provides an antibody which has the following features, its active fragment, or a derivative thereof: a) It specifically binds to human platelet membrane glycoprotein VI (GPVI); b) The function to activate a platelet and/or the function to induce a thrombocytopenia in vivo are low; and c) It at least partially depletes GPVI on the platelet membrane by contacting with a platelet. | 2014-02-13 |
20140044724 | ANTI-ENDOGLIN ANTIBODIES AND KNOCKIN MICE EXPRESSING NOVEL HUMAN/MOUSE CHIMERIC ENDOGLIN - Provided are compositions and methods that relate to prophylaxis and therapy of angiogenesis associated disease and includes novel knockin mice which express novel human/mouse chimeric endoglin, vectors for use in making such mice, and murine embryonic stem cells comprising the novel human/mouse transgene. Also provided are anti-human endoglin monoclonal antibodies (mAbs) which can be used as antiangiogenic agents for prophylaxis or therapy of human tumor angiogenesis and human angiogenesis-associated diseases having excessive vascularization. The mAbs do not cross react with murine endoglin. Also provides are methods for using the anti-human endoglin mAbs for prophylaxis or therapy of human tumor angiogenesis and for angiogenesis-associated diseases having excessive vascularization. | 2014-02-13 |
20140044725 | ALZHEIMER'S DISEASE TREATMENT METHOD - The invention relates to antibodies which are used in the preparation of a medicament for the treatment of Alzheimer's disease. More specifically, the invention relates to the use of an antibody specifically recognizing any one of the predominant variants of the amyloid beta peptide, Aβ40 and Aβ42, in the preparation of a medicament that is used to prevent and/or treat Alzheimer's disease. | 2014-02-13 |
20140044726 | PREPARATIONS AND METHODS FOR TREATING MALIGNANCIES - Disclosed are therapeutic formulations comprising antibodies against the PEKRAEKIWK eptiope of the monomeric isoform of A-protein and a physiologically acceptable carrier. Methods for the treatment of subjects using these therapeutic formulations are also disclosed. | 2014-02-13 |
20140044727 | FORMULATIONS WITH REDUCED VISCOSITY - The present invention is directed to a method for reducing the viscosity of a formulation containing acetate and a therapeutic protein and formulations made using the claimed method. | 2014-02-13 |
20140044728 | ANTI-TIM-3 ANTIBODY - Disclosed are an anti-human TIM-3 antibody having high ADCC activity or antibody fragment thereof by screening a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; and a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient. | 2014-02-13 |
20140044729 | ANTIBODY AND ANTIGEN RECOGNIZING TUMOR-INITIATING CELLS AND USE THEREOF - Disclosed is a method for searching, identifying, or validating a marker CACNA2D1 of tumor-initiating cells. The method comprises a step of immuninizing an animal using HEP-12 cells originating from a recurrent tumor and rich in originating cells. Also disclosed is a monoclonal antibody specially recognizing CACNA2D1 or antigen-binding fragments thereof, and the use thereof for treating or preventing tumors or diseases or conditions related to CACNA2D1. | 2014-02-13 |
20140044730 | ANTI-PCSK9 ANTIBODIES WITH pH-DEPENDENT BINDING CHARACTERISTICS - The present invention provides antibodies and antigen-binding fragments thereof that specifically bind proprotein convertase subtilisin/kexin-9 (PCSK9) with greater affinity at neutral pH than at acidic pH. The antibodies of the invention may possess one or more amino acid changes as compared to antibodies that do not exhibit pH-dependent binding properties. For example, the present invention includes anti-PCSK9 antibodies which possess one or more histidine substitutions in one or more complementarity determining regions. The antibodies of the invention, with pH-dependent binding properties, remain in circulation and exhibit cholesterol lowering activity for prolonged periods of time in animal subjects as compared to anti-PCSK9 antibodies that do not exhibit pH-dependent binding properties. The antibodies of the invention are therefore useful for treating diseases and disorders related to elevated HDL cholesterol, wherein the antibodies of the invention can be administered to a patient at a lower dose and/or with less frequent dosing as compared to antibodies that do not exhibit pH-dependent binding properties. | 2014-02-13 |
20140044731 | METHODS OF TREATING AGE-RELATED MACULAR DEGENERATION - The present invention is directed to methods of treating and diagnosing age-related macular degeneration. | 2014-02-13 |
20140044732 | Nucleic Acids Encoding Antibody Molecules Which Bind IL-17A and IL-17F - The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2014-02-13 |
20140044733 | ANTIBODY BASED REAGENT THAT SPECIFICALLY RECOGNIZES TOXIC OLIGOMERIC FORM OF BETA-AMYLOID - The invention relates to antibodies, antibody fragments and binding agents that specifically recognizes oligomeric Aβ that is resistant to denaturation by SDS but does not bind monomeric, fibrillar or other oligomeric forms of Aβ that are generated in vitro. | 2014-02-13 |
20140044734 | METHOD FOR TREATING LIVER INFLAMMATION, FIBROSIS AND NON-ALCOHOLIC STEATOHEPATITIS - The invention is in the field of prevention and medical treatment of liver diseases, in particular non-alcoholic steatohepatitis (NASH). The invention provides means and methods for the treatment of hepatic inflammation, fibrosis and more in particular NASH. More in particular, the invention provides a composition capable of raising anti-oxLDL antibodies in vivo for use in the treatment of liver inflammation or fibrosis. | 2014-02-13 |
20140044735 | METHODS TO CHARACTERIZE PATIENTS SUFFERING FROM HEMOLYSIS - The present invention relates to methods for determining the risk of severe complications in hemolytic diseases. The present invention relates to a method for determining whether a patient suffering from sickle cell disease is at risk for a vaso-occlusive crisis comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles. The present invention also relates to a method for a method the severe complication in hemolytic diseases comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles. The present invention also relates to a method for preventing a vaso-occlusive crisis in a patient afflicted with by sickle cell disease comprising depleting the blood-borne microparticles laden in heme and hemoglobin from the blood of said patient. | 2014-02-13 |
20140044736 | PROCOLLAGEN CARBOXY-TERMINAL PROPEPTIDES AS A TARGET AND TREATMENT FOR ANGIOGENESIS RELATED DISEASES - The present invention relates to the field of angiogenesis. More specifically, the present invention provides methods and compositions for modulating angiogenesis. In a specific embodiment, a method for modulating a blood vessel in a subject in need thereof comprising contacting a cell of the subject with a procollagen carboxy-terminal propeptide, a biologically active fragment or mimetic thereof, thereby modulating the blood vessel. | 2014-02-13 |
20140044737 | RBP4 IN INSULIN SENSITIVITY/RESISTANCE, DIABETES, AND OBESITY - Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity. | 2014-02-13 |
20140044738 | Antibodies And Other Molecules That Bind B7-H1 And PD-1 - The present invention relates to antibodies and their antigen-binding fragments and to other molecules that are capable of immunospecifically binding to B7-H1 or PD-1. In some embodiments such molecules are additionally capable of modulating the ability of B7-H1 or B7-DC to bind to PD-1 or are capable of affecting the signaling activity of the B7-H1 or PD-1. The invention additionally concerns the uses of such molecules in the diagnosis and treatment of cancer and other diseases. | 2014-02-13 |
20140044739 | CDIM Binding Proteins And Uses Thereof - The present disclosure relates to Cell Death Inducing Molecule (“CDIM”) binding proteins and pharmaceutical compositions thereof. Particularly, the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells, including neoplastic B cells as well as neoplastic cells that are not of B-cell origin that express CDIM-like antigens. In addition, the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins, and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative- and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins. | 2014-02-13 |
20140044740 | Diagnostic and Therapeutic Targets for Leukemia - The present invention relates to methods of identifying candidate compounds for the treatment of leukemia and diagnostic methods based on histone methylation and HoxA5 promoter activity. | 2014-02-13 |
20140044741 | B-TYPE PLEXIN ANTAGONISTS AND USES THEREOF - The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide. | 2014-02-13 |
20140044742 | METHOD FOR PREPARING A DEPLETED PLASMA MATERIAL CONSISTING OF ONE OR MORE THROMBOGENIC FACTORS - The invention concerns a method for preparing a plasma product depleted of one or more thrombogenic factors, comprising the combination of at least two steps chosen from among an ethanol fractionation step, a filtration-adsorption step, a precipitation step with caprylic acid and a chromatography step on ion exchange resin. | 2014-02-13 |
20140044743 | METHOD FOR ENHANCING IMMUNE RESPONSE WITH PEPTIDE - An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine. | 2014-02-13 |
20140044744 | NOVEL HYPOALLERGENS - The present invention provides mutant polypeptides useful as hypoallergens. More specifically the present invention provides mutant Bet v 1 proteins and the use of such polypeptides as hypoallergens for desensitizing against birch pollen allergies. Furthermore, the invention provides vaccine formulations comprising such polypeptides; the use of such formulations; and to methods of vaccination against birch pollen allergy. | 2014-02-13 |
20140044745 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 2014-02-13 |
20140044746 | MONOMERIC AND MULTIMERIC IMMUNOGENIC PEPTIDES - The present invention relates to novel peptides and methods for inducing an immune response in a subject against an antigen and for treatment, diagnosis and prognosis of infections or autoimmune diseases including infections with HCV, HIV, CMV and Flu. The invention further relates to methods for identifying and providing peptides useful for the treatment and diagnosis. | 2014-02-13 |
20140044747 | COMBINATION VACCINE - The disclosure relates to a composition comprising two or more immunogenic staphylococcal polypeptides and a multivalent vaccine composition comprising the immunogenic staphylococcal polypeptides. | 2014-02-13 |
20140044748 | METHODS FOR PREPARING COMPLEX MULTIVALENT IMMUNOGENIC CONJUGATES - Methods for preparing complex multivalent immunogenic conjugates that include simultaneously reacting a plurality or immunogenic-distinct polysaccharides with at least one protein to make the complex multivalent immunogenic conjugates. The simultaneous reaction involves reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. | 2014-02-13 |
20140044749 | VACCINES AGAINST CLOSTRIDIUM DIFFICILE AND METHODS OF USE - Attenuated microorganisms expressing | 2014-02-13 |
20140044750 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION - The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof. | 2014-02-13 |
20140044751 | RSV IMMUNIZATION REGIMEN - The invention relates to an immunization regimen whereby an infant is protected against respiratory syncytial virus (RSV) through administration of a first anti-RSV immune response inducing composition to his or her mother during pregnancy, followed by administration of a second anti-RSV immune response inducing composition to the infant after birth. | 2014-02-13 |
20140044752 | INACTIVATED VIRUS COMPOSITIONS AND METHODS OF PREPARING SUCH COMPOSITIONS - The present invention is directed at a composition comprising a live swine flu virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. Preferably, the formaldehyde donor agent is selected from a non-crosslinking chemical fixative that contains urea. | 2014-02-13 |
20140044753 | COMPOSITION CONTAINING INORGANIC NANOPARTICLES AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING OF ANGIOGENESIS-RELATED DISEASES - Provided is a pharmaceutical composition containing inorganic nanoparticles selected from titanium oxide nanoparticles or silica nanoparticles as an active ingredient for preventing or treating angiogenesis-related diseases. The pharmaceutical composition for preventing or treating angiogenesis-related diseases according to the present invention may be used as a therapeutic agent for various diseases based on angiogenesis such as age-related macular degeneration, tumors, and diabetes-related complications. | 2014-02-13 |
20140044754 | TDF-RELATED COMPOUNDS AND ANALOGS THEREOF - The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders. | 2014-02-13 |
20140044755 | RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF KRAS GENE - The present invention provides a composition for suppressing the expression of a KRAS gene, comprising a lipid particle containing, as a drug, a double-stranded nucleic acid having an antisense strand having a sequence of bases complementary to the sequence of at least 19 continuous bases of any one KRAS gene's mRNA of sequence Nos. 1 to 3; and | 2014-02-13 |
20140044756 | MULTILAYER NANOFIBER FILTER - A method of making a multilayer filter and the multilayer filter made by the method. The method includes generally two steps. The first step is to coat a layer of nanofibers on a single side or both sides of a substrate medium to obtain a composite filter medium, and the second step is to fold the composite filter medium in a serpentine fashion to form a multilayer filter. The second step may alternatively be accomplished by stacking up a number of sheets of the composite filter medium to form a multilayer filter having a structure of two layers of nanofibers being sandwiched between two layers of said substrate medium. The resulting multilayer filter produced by either method contains at least one structural unit which has two layers of nanofibers being sandwiched between two layers of the substrate medium. | 2014-02-13 |
20140044757 | METHOD FOR SELECTIVELY INHIBITING ACAT1 IN THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention features methods for stimulating clearance of amyloid beta in microglia, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the expression or activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2. | 2014-02-13 |
20140044758 | WOUND DRESSING WITH BACTERIOSTASIS AND HYGROSCOPICITY - A wound dressing with bacteriostatic and hygroscopicity, preparation method therefore, and the use thereof in preparing a product for treating chronic wounds. The dressing comprises chitosan fiber and modified cellulose fiber. | 2014-02-13 |
20140044759 | DRUG SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREPARING THE SAME - Drug substances, which comprise a solid amorphous forms of a compound of structural formula I and have a BET specific surface area of up to about 94 m | 2014-02-13 |
20140044760 | STABLE, FLOWABLE SILICA CAPSULE FORMULATION - A flowable, stable silica capsule formulation composed of a silica capsule suspension and an adjuvant for use in a personal care product, a beauty care product, a fabric care product, a home care product, a personal hygiene product, an oral care product is provided. | 2014-02-13 |
20140044761 | HYBRID FRAGRANCE ENCAPSULATE FORMULATION AND METHOD FOR USING THE SAME - A hybrid encapsulate formulation obtained by mixing a starch/fragrance emulsion with a core-shell capsule suspension is provided as is a method of using the formulation in a personal care product, a beauty care product, a fabric care product, a home care product, a personal hygiene product, an oral care product and a method for releasing an encapsulated fragrance by moisture, shear, or a combination thereof. | 2014-02-13 |
20140044762 | Wash Resistant Compositions Containing Aminosilicone - Compositions and methods are disclosed for imparting a long-wearing color to keratin fibers, including hair. More specifically, the invention relates to cosmetic compositions and methods for improving retention of particulate materials, such as pigments, on hair to artificially color the hair and/or to impart other aesthetic benefits to the hair. The compositions comprise at least one aminosilicone polymer having at least one diamino functional group, and a functional group equivalent weight (FGEW) from about 1,000 to about 2,000 g/mol and a non-spherical | 2014-02-13 |
20140044763 | COLLOIDAL SOLUTION OF SILVER NANOPARTICLES AND METHOD OF IT PREPARATION - The invention relates to colloidal solutions of silver nanoparticles and to method of it preparation and can be used in different areas, particularly in medicine, veterinary science, food industry, cosmetology, household chemistry and agrochemistry. Method includes the electrochemical dissolution of silver in the deionized water. The silver in fine powder form with chemical purity of 99.999% and with nanoparticle sizes up to 100 nm is subjected to electrochemical dissolution in electrolyser, within which are located the electrodes in form of containers made from chemically neutral material, in which fine powder of silver from 100 to 150 g are placed, and by means of conductor covered by chemically neutral coat the direct voltage ranges from 30 to 45 volts is energized. Electrolysis is proceeded under conditions of cycling voltage polarity every 2 hours and mechanical stirring of solution 2 times in twenty-four hours until the concentration of silver in colloidal solution from 5.0 to 100 mg/l. Wherein the portion of silver metal nanoparticles is from 5 to 90% of total concentration of silver in solution, the portion of nanoparticles ranging from 2 to 15 nm is from 65 to 85% of total volume of silver metal nanoparticles in solution, the portion of nanoparticles ranging from 15 to 35 nm is correspondingly from 15 to 35%, the residual portion of total silver concentration in solution is silver ions. The technical result of invention is preparation of the stable colloidal solution of silver nanoparticles. | 2014-02-13 |
20140044764 | USE OF 2,3,3,3-TETRAFLUOROPROPENE/VINYLIDENE FLUORIDE COPOLYMERS TO PREVENT BIOFOULING - A copolymer comprising 2,3,3,3-tetrafluoropropene and vinylidene fluoride and having a surface energy of between about 20 and about 30 mJ/m | 2014-02-13 |
20140044765 | STABLE FORMULATION - Disclosed is a composition comprising (a) a pesticidally effective amount of mineral oil; and (b) a suspension concentrate comprising particulate sulfur suspended in an aqueous medium and a method for using the same for the treatment of a locus. | 2014-02-13 |
20140044766 | METHOD FOR THE ANTIMICROBIAL PROTECTION OF AN OBJECT USING AN ANTIMICROBIAL PRESSURE-SENSITIVE ADHESIVE PLASTICS FILM - The present invention relates to a method for the antimicrobial protection of a plane or non-plane surface of a material object, i.e. other than a human or animal body, characterized in that the face termed the inner face of a self-adhesive plastics film ( | 2014-02-13 |
20140044767 | COMPOSITION AND METHOD OF USE FOR A COCKROACH KILLING INSECTICIDE - A chemical composition to kill a plurality of cockroaches comprising: boric acid, where the boric acid is utilized to kill the cockroaches; flour, where the flour serves as a binding agent; sugar, where the sugar baits and attracts the cockroaches; and water, where the water combines the boric acid, the flour, and the sugar to create a mixture and then the mixture is placed in a specific location where cockroaches are anticipated to be. The sugars used may be powered sugar or brown sugar to attract the cockroaches. | 2014-02-13 |
20140044768 | IMPLANTABLE DEVICES COATED WITH INSULIN-MIMETIC AGENT COMPOSITES AND METHODS THEREOF - The present invention discloses vanadium-based insulin-mimetic agent composite coatings, application of these coatings onto implantable devices, and use of the implantable devices for accelerating osseous healing. The invention also encompasses methods of manufacturing implantable devices coated with vanadium-based insulin-mimetic agent composite coatings and the implantable devices so manufactured. The implantable devices have wide applications, including but not limited to treating bone fracture, bone trauma, arthrodesis, and other bone deficit conditions, as well as bone injuries incurred in military and sports activities. | 2014-02-13 |
20140044769 | COMPOSITE ABSORBABLE/BIODEGRADABLE RINGS FOR CONTROLLED DRUG DELIVERY - A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer. | 2014-02-13 |
20140044770 | Compositions and Methods for Modulating BRD4 Bioactivity - Compositions and methods for increasing or decreasing DNA repair are provided. Composition includes a Brd4 polypeptide, fragment, fusion, or variant thereof. The fusion protein can include a protein transduction, a targeting domain, or a combination thereof to enhance delivery of the fusion protein to the interior of a particular target cell, such as a cancer cell. Inhibitory nucleic acids that target a Brd4 mRNA and antibodies that target a Brd4 polypeptide are also disclosed. The inhibitory nucleic acid or antibody can target a sequence or epitope on Brd4 isoform B that is absent on Brd4 isoform A and Brd4 isoform C. Methods for increasing or decreasing the sensitivity of cells to a DNA damaging agent, methods of treating cancer, and methods of determining cells' sensitivity to a DNA damaging agent are also disclosed. | 2014-02-13 |
20140044771 | ENZYME PRODRUG CANCER THERAPY SELECTIVELY TARGETED TO TUMOR VASCULATURE AND METHODS OF PRODUCTION AND USE THEREOF - Methods of treating cancer by targeting tumor vasculature using an enzyme prodrug cancer therapy treatment are provided. | 2014-02-13 |
20140044772 | LIPOSOMAL APPARATUS AND MANUFACTURING METHODS - The present invention provides apparatus and processes for producing liposomes. By providing a buffer solution in a first reservoir, and a lipid solution in a second reservoir, continuously diluting the lipid solution with the buffer solution in a mixing chamber produces a liposome. The lipid solution preferably comprises an organic solvent, such as a lower alkanol. | 2014-02-13 |
20140044773 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 2014-02-13 |
20140044774 | SYSTEMS AND METHODS FOR TREATMENT OF ALLERGIES AND OTHER INDICATIONS - The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising an H | 2014-02-13 |
20140044775 | SYNTHETIC LUNG SURFACTANT AND USE THEREOF - The present invention relates to synthetic lung surfactant compositions that contain one or more of phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active proteins or peptides, more preferably a combination of at least two or all three of these materials. Novel phospholipase-resistant phospho-glycerol derivatives, phospholipase-resistant phospho-choline derivatives, and surface active peptides are also disclosed herein. Uses of the surfactant compositions of the present invention to treat endogenous surfactant dysfunctional or deficient lung tissue, to prepare synthetic peptides for use in the surfactant compositions, and to deliver therapeutic agents are also disclosed. | 2014-02-13 |
20140044776 | SERPIN DRUGS FOR TREATMENT OF VIRAL INFECTION AND METHOD OF USE THEREOF - The invention includes a heparin activated Antithrombin III encapsulated into a sterically stabilized anti-HLA-DR immunoliposome for the treatment of a HIV infection in a human patient. | 2014-02-13 |
20140044777 | Liposome Composition - The present invention provides a novel liposome composition containing eribulin or its pharmacologically permissible salt, and its method of manufacture. | 2014-02-13 |
20140044778 | NANOPARTICLES CONTAINING pH-RESPONSIVE PEPTIDE - The present invention provides a nanoparticle and cell induction agent, capable of releasing a target substance in a weakly acidic pH environment. Specifically, the present invention provides a nanoparticle comprising a peptide and a particle-forming component, the particle-forming component forming a liposome or a micelle, the peptide having a sequence with 2 to 8 units starting with His (histidine) and ending with an acidic amino acid, wherein each of the units may be identical or different. | 2014-02-13 |
20140044779 | Liquid Carrier for Oral Delivery of a Pharmacologically Active Agent - A fluid carrier comprises first and second substantially immiscible liquids. The first liquid is an open-chain silicone oil of the formula [(CH | 2014-02-13 |
20140044780 | Extended-Release Levetiracetam and Method of Preparation - Described herein is a pharmaceutical composition comprising levetiracetam as an active ingredient to provide prolonged release characteristic to allow once a day dosage regime. The innovative formulation comprises levetiracetam and a hydrophobic polymer with or without additional release rate modifier(s). The formulation may comprise other pharmaceutically acceptable excipients. This invention also describes the processes of preparing such dosage forms. | 2014-02-13 |
20140044781 | Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof - The present invention relates provides pharmaceutical compositions comprising an amorphous carvedilol salt and one or more pharmaceutically acceptable excipients, wherein the amorphous carvedilol salt is formed in situ during the preparation of the pharmaceutical composition. The amorphous carvedilol salt is preferably an amorphous carvedilol phosphate salt. The pharmaceutical compositions can be prepared by providing one or more inert cores; contacting the core or cores with a solution or a dispersion comprising carvedilol, an acid component and optionally a binder, in a solvent; removing the solvent; and optionally coating the core or cores with an extended release composition. Preferred pharmaceutical compositions contain both immediate-release pellets and at least one population of extended-release pellet. | 2014-02-13 |
20140044783 | PHARMACEUTICAL COMPOSITION COMPRISING A THIAZOLIDINEDIONE - A pharmaceutical composition comprises a combination of thiazolidinedione or a pharmaceutically acceptable salt thereof as a first pharmaceutically active ingredient and a second pharmaceutically active ingredient different from thiazolidinedione, wherein the amount of said second pharmaceutically ingredient is larger than that of the first pharmaceutically active ingredient, and wherein the combination of said first and second pharmaceutically active ingredients are provided by a first granulate comprising the first and second pharmaceutically active ingredients and optionally at least one excipient, said first granulate being present in a second granulate comprising a further pharmaceutical excipient. | 2014-02-13 |
20140044784 | COMBINED FORMULATION WITH IMPROVED STABILITY - Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability. | 2014-02-13 |
20140044785 | MICROPOROUS ZIRCONIUM SILICATE FOR THE TREATMENT OF HYPERKALEMIA - The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia. | 2014-02-13 |
20140044786 | ONCE-WEEKLY ORAL ADMINISTRATION OF ARIPIPRAZOLE - An orally deliverable pharmaceutical composition provides controlled release of aripiprazole. The composition includes a therapeutically effective amount of aripiprazole and at least one pharmaceutically acceptable excipient. The compositions of the invention may exhibit one or more of the release profiles defined in the specification. | 2014-02-13 |
20140044787 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS - The present application discloses a sustained release composition in pellet form, wherein the core of the pellet comprises:
| 2014-02-13 |
20140044788 | Solid Oral Formulations of a Pyridopyrimidinone - A solid oral dosage pharmaceutical formulation of (R)-2-Amino-7-[4-fluoro-2-(6-methoxy-pyridin-2-yl)-phenyl]-4-methyl-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one or its salt; and a surfactant or an acid. | 2014-02-13 |
20140044789 | MELANIN NANOSHELLS FOR PROTECTION AGAINST RADIATION AND ELECTRONIC PULSES - This invention provides melanin nanoshells and their use for protection against radiation, particularly ionizing radiation, and electronic pulses, and methods of making materials comprising melanin nanoshells. | 2014-02-13 |
20140044790 | APPARATUS AND METHOD FOR CRYOGRANULATING A PHARMACEUTICAL COMPOSITION - Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing. | 2014-02-13 |
20140044791 | TARGETED NANOPARTICLE CONJUGATES - A composition for treating a disorder in a subject includes a polyethylene glycolylated (PEGylated) nanoparticle, at least one hydrophobic therapeutic agent coupled to the surface of the nanoparticle; and at least one targeting moiety coupled to polyethylene glycol of the nanoparticle for targeting the composition to a cell associated with disorder. | 2014-02-13 |
20140044792 | Method for Producing an Implantable Bone Composition - Methods for producing implantable bone compositions suitable for attaching stem cells thereto, characterized in that bone particles are contacted with an albumin comprising solution. Said bone particles can be mineralized and/or lyophilized bone particles of animal or human origin. Preferably the non-immunogenic albumin comprising solution is lyophilized onto said bone particles. The invention further concerns bone compositions suitable for usin in graft implantation obtainable by said methods. | 2014-02-13 |
20140044793 | MICROENCAPSULATION PROCESS AND PRODUCT - A composition comprising a core material, having a taste value and a polymeric coating. The polymeric coating substantially surrounds the core material and comprises a cationic polymer and optionally an anionic polymer. The polymeric coating has a uniform thickness ranging from 2 μm to 20 μm. The composition provides release of a portion of the core material which is taste masked over a time period ranging from 0.5 minute to 2 minutes in the oral cavity and provides a modified-release of the remaining core material in a gastrointestinal tract. | 2014-02-13 |
20140044794 | Drug Delivery Particle and Method for Producing the Same - An object of the present invention is to develop and provide a method for conveniently introducing a nucleic acid, a peptide, and/or a low-molecular-weight compound into an empty capsid with viral early infection activities kept. The present invention provides a method for producing a drug delivery particle, comprising the steps of: mixing an empty capsid or an empty particle with a drug including a nucleic acid, a peptide, and/or a low-molecular-weight compound in a solution comprising 0.1 to 20% of a surfactant; and keeping the obtained mixed solution at −5 to 50° C. to introduce the drug into the empty capsid or the empty particle. | 2014-02-13 |
20140044795 | COMPOSITION WITH GROWTH FACTORS, TO BE USED IN THE INTRANASAL TREATMENT OF A NEURODEGENERATIVE DISEASE OR OTHER DISEASES OF THE CENTRAL NERVOUS SYSTEM, AND ITS METHOD OF MANUFACTURE - The object of the invention is the treatment of neurodegenerative diseases or other applicable diseases by means of the intranasal administration of a composition obtained from at least one growth-factor-containing blood compound, or by means of a therapeutic substance obtained from said composition, in addition to the composition itself. It is guaranteed that the composition reaches the central nervous system in an effective manner in terms of the treatment, and also in a safe manner for the patient. | 2014-02-13 |
20140044796 | DETECTION AND REMOVAL OF MISFOLDED PROTEINS/PEPTIDES - The invention concerns the field of detecting and quantifying misfolded proteins/peptides. In particular the detection and quantification of misfolded proteins/peptides in body fluids, on cell surfaces of humans and mammals, the detection of misfolded proteins/peptides in reagents to be tested for scientific research and/or diagnostic use and in pharmaceutical medication or their additives and it concerns as well the removal of misfolded proteins/peptides from reagents to be tested for scientific research and/or for diagnostic purposes and from pharmaceutical medication or their additives. Furthermore the invention includes substances to identify and methods to detect bio-films, a method to examine hemocompatibility of materials and a method to optimize therapeutical products, and to provide reagents microorganisms to charge with for more reliable diagnostics and quality control of biopharmaceuticals and identification substances for the screening for preliminary stages of amyloids that can be used for technical purposes. | 2014-02-13 |